katie kelley, md, discusses fitting tremelimumab durvalumab into hcc treatment algorithms
Published 4 years ago • 138 plays • Length 3:57
Download video MP4
Download video MP3
Similar videos
-
3:44
katie kelley, md, explains the design of the phase 2 study 22 in hcc cancer patients
-
0:51
katie kelley, md, differentiates the himalaya study from study 22 and i-o adoption in hcc treatment
-
3:31
katie kelley, md, provides thoughts on the potential practice changing study 22 results
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
28:11
hepatocellular carcinoma - molecular approaches to treatment
-
0:51
dr. kelley on the development of biomarkers for hcc
-
7:48
himalaya: study of tremelimumab and durvalumab as first-line therapy in patients with uhcc
-
3:34
himalaya: does underlying liver function impact efficacy of tremelimumab plus durvalumab for hcc?
-
1:20
dr. kelley discusses rising incidences of hcc
-
2:48
kevin p. bethke, md
-
20:34
overview of data for immunotherapy - katie kelley, ucsf (d2p16)
-
1:11
dr. kelley on newly approved agents in hcc
-
3:18
new treatment option for advanced kidney cancer
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
1:15
montblanc: sequential or up-front durvalumab, tremelimumab, bevacizumab in unresectable hcc
-
5:30
pivotal data supporting first-line durvalumab/tremelimumab in unresectable hcc
-
7:15
checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
-
7:47
combination tremelimumab and durvalumab in hcc
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
Clip.africa.com - Privacy-policy